These results are consistent with mechanistic studies highlighting that inflammatory signaling is linked with cell-cycle progression promoting the progression of MDS to AML-MRC and affecting the disease biology and sensitivity to current therapies [93,97,98,99,100,101]. This evidence concerns the gene CD200 and acute myeloid leukemia.